Prevention of chronic Pseudomonas aeruginosa infection in people with cystic fibrosis

Expert Review of Respiratory Medicine

Volumn 3, Issue 4, 2009, Pages 349-361

  Conway, Steven P ^a   Lee, Tim W R ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Ciprofloxacin; Colistin; Eradication; Infection control; Tobramycin

Indexed keywords

CIPROFLOXACIN; COLISTIN; IMMUNOGLOBULIN Y; INTERLEUKIN 1BETA; INTERLEUKIN 8; LEUKOCYTE ELASTASE; MOUTHWASH; PLACEBO; PSEUDOMONAS VACCINE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTERIAL TRANSMISSION; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTERIUM DETECTION; BRONCHOSPASM; CLINICAL TRIAL; CROSS INFECTION; CYSTIC FIBROSIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FORCED EXPIRATORY VOLUME; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LUNG LAVAGE; NEBULIZER; NEPHROTOXICITY; NEUTROPHIL COUNT; NONHUMAN; OTOTOXICITY; PHOTODERMATOSIS; PSEUDOMONAS INFECTION; PSYCHOSOCIAL CARE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SPUTUM CULTURE;

EID: 70149083069     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.26     Document Type: Review

References (109)

1. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073 (1989).
2. Farrell PM. The prevalence of cystic fibrosis in the European Union. J. Cyst. Fibros. 7, 450-453 (2008).
3. Cystic Fibrosis Foundation patient registry 2006. Annual Data Report. CF Foundation, Bethesda, MD, USA (2008).
4. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur. Resp. J. 29, 522-526 (2007).
5. Matsui H, Grubb BR, Tarran R et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95, 1005-1015 (1998).
6. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Resp. J. 23, 146-158 (2004).
7. Morgan WJ, Butler SM, Johnson CA et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr. Pulmonol. 28, 231-241 (1999).
8. Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc. Natl Acad. Sci. USA 92, 3019-3023 (1995).
9. Worlitzsch D, Tarran R, Ulrich M et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109, 317-325 (2002).
10. Duguépéroux I, Hubert D, Dominique S, Bellis G, De Braekeleer M, Durieu I. Paternity in men with cystic fibrosis: a retrospective survey in France. J. Cyst. Fibros. 5, 215-221 (2006).
11. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am. J. Dis. Child. 56, 344-399 (1938).
12. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151, 1075-1082 (1995).
13. Armstrong DS, Grimwood K, Carlin JB et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 156, 1197-1204 (1997).
14. Rosenfeld M, Gibson RL, McNamara S et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr. Pulmonol. 32, 356-366 (2001).
15. Burns JL, Gibson RL, McNamara S et al. Longitudinal assessment of Pseudomonas aeruginosa in children with cystic fibrosis. J. Infect. Dis. 183, 444-452 (2001).
16. Douglas TA, Brennan S, Gard S et al. Acquisition and eradication of Pseudomonas aeruginosa in young children with cystic fibrosis. Eur. Resp. J. 33, 305-311 (2009).
17. Teichgräber V, Ulrich M, Endlich N et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 14, 382-391 (2008).
18. Sagel SD, Gibson RL, Emerson J et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J. Pediatr. 154, 183-188 (2009).
19. Dakin CJ, Numa AH, Wang H, Morton JR, Vertzyas CC, Henry RL. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 165, 904-910 (2002).
20. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonisation with Pseudomonas aeruginosa. J. Pediatr. 116, 714-719 (1990).
21. Kosorok MR, Zeng L, West SHE et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Paediatr. Pulmonol. 32, 277-287 (2001).
22. Nixon GM, Armstrong DS, Carzino R et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J. Pediatr. 138, 699-704 (2001).
23. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Paediatr. Pulmonol. 34, 91-100 (2002).
24. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. 29-34 (2003).
25. McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and Dornase-α use. J. Pediatr. 153, 752-757 (2008).
26. Kozlowska WJ, Bush A, Wade A et al. Lung function from infancy to the pre-school years after clinical diagnosis of cystic fibrosis. Am. J. Respir. Crit. Care Med. 178, 42-49 (2008).
27. Frederiksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr. Pulmonol. 28, 159-166 (1999).
28. Proesmans M, Balinska-Miskiewicz W, Dupont L et al. Evaluating the 'Leeds criteria' for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur. Resp. J. 27, 937-943 (2006).
29. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonisation in CF patients: 15 years experience. J. Cyst. Fibros. 7, 523-530 (2008).
30. Shwachman H, Kulczycki LL. Long term study of one hundred and five patients with cystic fibrosis. Am. J. Dis. Child. 96, 6-15 (1958).
31. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev. 25(1), CD004197 (2006).
32. Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in people with cystic fibrosis. Ped. Pulmonol. 42, 751-756 (2007).
33. Courtney JM, Bradley J, McCaughan J et al. Predictors of mortality in adults with cystic fibrosis. Pediatr. Pulmonol. 42, 525-532 (2007).
34. 1 in children and adolescents with cystic fibrosis. J. Pediatr. 151, 134-139 (2007).
35. Doring G, Hoiby N; Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cyst. Fibros. 3, 67-91 (2004).
36. Lee TW, Brownlee KG, Denton M, Littlewood JM, Conway SP. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis centre. Pediatr. Pulmonol. 37, 104-110 (2004).
37. Hoiby N, Pedersen SS. Estimated risk of cross infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr. Scand. 78, 395-404 (1989).
38. Cheng K, Smyth RL, Govan JR et al. Spread of a β-lactam resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 7, 639-642 (1996).
39. Brimicombe RW, Dijkshoorn L, Van der Reijden TJK et al. Transmission of Pseudomonas aeruginosa in children with cystic fibrosis attending summer camps in the Netherlands. J. Cyst. Fibros. 7, 30-36 (2007).
40. Koch C, Frederiksen B, Hoiby N. Patient cohorting an infection control. Semin. Respir. Crit. Care Med. 24, 703-715 (2003).
41. Griffiths AL, Jamsen K, Carlin JB et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am. J. Respir. Crit. Care Med. 171, 1020-1025 (2005).
42. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Hoiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J. Cyst. Fibros. 7, 391-397 (2008).
43. Denton M, Kerr K, Mooney L et al. Transmission of Colistin resistant Pseudomonas aeruginosa between patients attending a paediatric cystic fibrosis center. Pediatr. Pulmonol. 34, 257-261 (2002).
44. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient to patient transmission. Infect. Control Hosp. Epidemiol. 24, S6-S52 (2003).
45. Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 132, 550-568 (2007).
46. Ferroni A, Werkhauser-Bertran DA, Lebourgeios M et al. Bacterial contamination in the environment of hospitalised children with cystic fibrosis. J. Cyst. Fibros. 7, 477-482 (2008).
47. Armstrong DS, Nixon GM, Carzino R et al. Detection of a widespread clone of Pseudomonas aeruginosa in a paediatric cystic fibrosis clinic. Am. J. Respir. Crit. Care Med. 166, 983-987 (2002).
48. Jones AM, Dodd ME, Govan JRW et al. Prospective surveyance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am. J. Respir. Crit. Care Med. 171, 257-260 (2005).
49. Govan JRW, Brown AR, Jones AM. Evolving epidemiology of Pseudomonas aeruginosa and Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol. 2(2), 153-164 (2007).
50. Clifton IJ, Fletcher LA, Beggs CB, Denton M, Peckham DG. A laminar flow model of aerosol survival of epidemic and non-epidemic strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. BMC Microbiol. 8, 105 (2008).
51. Jones AM, Dodd ME, Doherty CJ, Govan JRW, Webb AK. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 57, 924-925 (2002).
52. Al-Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, Walshaw MJ. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59, 334-336 (2004).
53. Salunkhe P, Smart CHM, Morgan AW et al. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J. Bacteriol. 187, 4908-4920 (2005).
54. Jones AM, Govan JRW, Doherty C et al. Spread of a multi resistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 358, 557-558 (2001).
55. O'Carroll MR, Syrmis MW, Wainwright CE et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur. Resp. J. 24, 101-106 (2004).
56. Döring G, Jansen S, Noll H et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr. Pulmonol. 21, 90-100 (1996).
57. Griffiths AL, Armstrong D, Carzino R, Robinson P. Cystic fibrosis patients and families support cross-infection measures. Eur. Resp. J. 24, 449-452 (2004).
58. Russo K, Donnelly M, Reid AJM. Segregation - the perspectives of young patients and their parents. J. Cyst. Fibros. 5, 93-99 (2006).
59. Waine DJ, Whitehouse J, Honeybourne D. Cross infection in cystic fibrosis: the knowledge and behaviour of adult patients. J. Cyst. Fibros. 6, 262-266 (2007).
60. Garber E, Desai M, Zhou J et al. Barriers to adherence to cystic fibrosis infection control guidelines. Pediatr. Pulmonol. 43, 900-907 (2008).
61. Levy H, Kalish LA, Cannon CL et al. Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients. Pediatr. Pulmonol. 43, 463-471 (2008).
62. De Boeck K, Alifier M, Vandeputte S. Sputum induction in young cystic fibrosis patients. Eur. Resp. J. 16, 91-94 (2000).
63. Ho SA, Ball R, Morrison LJ, Brownlee KG, Conway SP. Clinical value of obtaining sputum and cough swab samples following inhaled hypertonic saline in children with cystic fibrosis. Paediatr. Pulmonol. 38, 82-87 (2004).
64. Ho SA, Lee TW, Denton M, Conway SP, Brownlee KG. Regimens for eradicating Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. J. Cyst. Fibros. 8, 43-46 (2009).
65. Govan JRW. Multidrug-resistant pulmonary infection in cystic fibrosis - what does 'resistant' mean? J. Med. Microbiol. 55, 1615-1617 (2006).
66. Alonso A, Campanario E, Martinez JL. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. Microbiology 145, 2857-2862 (1999).
67. Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 58, 794-796 (2003).
68. Smith A, Doershuk C, Goldmann D et al. Comparison of a b-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J. Pediatr. 134, 413-421 (1999).
69. Smith A, Fiel S, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration. Lack of association in cystic fibrosis. Chest 123, 1495-1502 (2003).
70. Foweraker JE, Laughton CR, Brown DFJ, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrobial Chemother. 55, 921-927 (2005).
71. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr. Pulmonol. 42, 249-255 (2007).
72. Brett MM, Ghoneim ATM, Littlewood JM. Prediction and diagnosis of early P. aeruginosa infection in cystic fibrosis: a follow-up study. J. Clin. Microbiol. 26, 1565-1570 (1988).
73. West SE, Zeng L, Lee BL et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 287, 2958-2967 (2002).
74. Farrell PM, Govan JRW. Pseudomonas serology: confusion, controversy, and challenges. Thorax 61, 645-647 (2006).
75. Munck A, Bonacorsi S, Mariani-Kurkdjian P et al. Genotypic characterisation of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonisation. Pediatr. Pulmonol. 32, 288-292 (2001).
76. Gibson RL, Emerson J, McNamara S et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Resp. Crit. Care Med. 167, 841-849 (2003).
77. Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur. Resp. J. 26, 458-461 (2005).
78. Littlewood JM, Miller MG, Ghonheim AT, Ramsden CH. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1(8433), 865 (1985).
79. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338, 725-726 (1991).
80. Wiesemann HG, Steinkamp G, Ratjen F et al. Placebo-controlled, double-blind, randomised study of aerosolised tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr. Pulmonol. 25, 88-92 (1998).
81. Ratjen F, Stenglein S, Munck A. Inhaled tobramycin nebuliser solution for treatment of early Pseudomonas aeruginosa infection: the ELITE study. J. Cyst. Fibros. 7, S26 (2008).
82. Denton M, Brownlee KG, Conway S, Lee T, Peckham D. Early eradication therapy for Pseudomonas aeruginosa: impact of prior clinical status and choice of antibiotic regimen on eradication rates. J. Cyst. Fibros. 5, S22 (2006).
83. Wainwright C, Carlin J, Cooper P et al. Australasian cystic fibrosis BAL study interim analysis. Ped. Pulmonol. 29, 317 (2006).
84. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multi-method assessment of treatment adherence for children with cystic fibrosis. J. Cyst. Fibros. 5, 177-185 (2006).
85. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob. Agents Chemother. 31, 594-599 (1987).
86. Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 41, 645-654 (2001).
87. Rosenfeld M, Gibson R, McNamara S et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J. Pediatr. 139, 572-577 (2001).
88. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122, 219-226 (2002).
89. Hodson ME, Gallagher CG, Govan JR. A randomised trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Resp. J. 20, 658-664.
90. Dodd ME, Abbott J, Maddison J, Moorcroft AJ, Webb AK. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 52, 656-658 (1997).
91. Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, Wallis C. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch. Dis. Child. 84, 432-433 (2001).
92. Alothman GA, Alsaadi MM, Ho BL et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 122, 930-934 (2002).
93. Ferguson J, McEwen J, Al-Ajmi H, Purkins L, Colman PJ, Willavize SA. A comparison of the photosensitizing potential of trovafloxin with that of the other quinolones in healthy subjects. J. Antimicrob. Chemother. 45, 503-509 (2000).
94. Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focussing on new mechanistic and clinical data. Int. J. Antimicrob. Agents 33, 194-200 (2009).
95. Becker JW, Burke W, McDonald G, Greenberger PA, Henderson WR, Aitken ML. Prevalence of allergic bronchopulmonary Aspergillosis and atopy in adult patients with cystic fibrosis. Chest 109, 1536-1540 (1996).
96. Shoseyov D, Brownlee KG, Conway SP, Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest 130, 222-226 (2006).
97. Byrne NM, Keavey PM, Perry JD, Gould FK, Spencer DA. Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Arch. Dis. Child. 88, 715-718 (2003).
98. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J. Pediatr. Psychol. 31, 846-858 (2006).
99. Kishida M, Suzuki I, Kabayama H et al. Mouthpiece versus facemask for delivery of nebulised salbutamol in exacerbated childhood asthma. J. Asthma 39, 337-339 (2002).
100. Denton M, Rajgopal A, Mooney L et al. Stenotrophomonas maltophilia contamination of nebulisers used to deliver aerosolised therapy to inpatients with cystic fibrosis. J. Hosp. Infect. 55, 180-183 (2003).
101. Bakuridze L, Andrieu V, Dupont C, Dubus JC. Does repeated disinfection of the e-Flow rapid nebuliser affect in vitro performance? J. Cyst. Fibro. 6, 309-310 (2007).
102. Latchford G, Duff A, Quinn J, Conway S, Conner M. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ. Couns. 75, 141-144 (2009).
103. Duff AJA, Latchford G, Moore MW, Riekert KA. Motivational interviewing skills for changing health behaviours. Pediatr. Pulmonol. (Suppl. 29), 10 (2006).
104. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst. Rev. 4, CD001399 (2008).
105. Döring G, Meisner C, Stern M. A double blind randomized placebo-controlled Phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 104, 11020-11025 (2007).
106. Nilsson E, Larsson A, Olesen HV, Wejaker PE, Kollberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr. Pulmonol. 43, 892-899 (2008).
107. Ullrich G, Wiedau S, Schulz W, Steinkamp G. Parental knowledge and behaviour to prevent environmental P. aeruginosa acquisition in their children with CF. J. Cyst. Fibros. 7, 231-237 (2008).
108. Goldbeck L, Zerrer S, Schmitz TG. Monitoring quality of life in outpatients with cystic fibrosis: feasibility and longitudinal results. J. Cyst. Fibros. 6, 171-178 (2007).
109. Lee TWR. Eradication of early Pseudomonas infection in cystic fibrosis. Chronic Respir. Dis. 6, 99-107 (2009).